Literature DB >> 33243844

EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR.

Marissa Borgese1, David Badesch2, Todd Bull2, Murali Chakinala3, Teresa DeMarco4, Jeremy Feldman5, H James Ford6, Dan Grinnan7, James R Klinger8, Lena Bolivar9, Oksana A Shlobin10, Robert P Frantz11, Jeffery S Sager12, Stephen C Mathai13, Steven Kawut14, Peter J Leary15, Michael P Gray16, Rita A Popat1, Roham T Zamanian17,18.   

Abstract

INTRODUCTION: While the performance of the emPHasis-10 (e10) score has been evaluated against limited patient characteristics within the United Kingdom, there is an unmet need for exploring the performance of the e10 score among pulmonary arterial hypertension (PAH) patients in the United States.
METHODS: Using the Pulmonary Hypertension Association Registry, we evaluated relationships between the e10 score and demographic, functional, haemodynamic and additional clinical characteristics at baseline and over time. Furthermore, we derived a minimally important difference (MID) estimate for the e10 score.
RESULTS: We analysed data from 565 PAH (75% female) adults aged mean±sd 55.6±16.0 years. At baseline, the e10 score had notable correlation with factors expected to impact quality of life in the general population, including age, education level, income, smoking status and body mass index. Clinically important parameters including 6-min walk distance and B-type natriuretic peptide (BNP)/N-terminal proBNP were also significantly associated with e10 score at baseline and over time. We generated a MID estimate for the e10 score of -6.0 points (range -5.0--7.6 points).
CONCLUSIONS: The e10 score was associated with demographic and clinical patient characteristics, suggesting that health-related quality of life in PAH is influenced by both social factors and indicators of disease severity. Future studies are needed to demonstrate the impact of the e10 score on clinical decision-making and its potential utility for assessing clinically important interventions.
Copyright ©ERS 2021.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33243844     DOI: 10.1183/13993003.00414-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  On errata and corrigenda-The Pulmonary Hypertension Association Registry (PHAR).

Authors:  Kayleen Williams; Noah A Kime; Richard A Kronmal; Nadine Al-Naamani
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

2.  Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective.

Authors:  Marc Humbert; Edmund M T Lau
Journal:  Am J Respir Crit Care Med       Date:  2021-03-15       Impact factor: 21.405

3.  Health-related quality of life and hospitalizations in chronic thromboembolic pulmonary hypertension versus idiopathic pulmonary arterial hypertension: an analysis from the Pulmonary Hypertension Association Registry (PHAR).

Authors:  Jasleen Minhas; Sai Prasanna Narasimmal; Todd M Bull; Teresa De Marco; John Wesley McConnell; Matthew R Lammi; Thenappan Thenappan; Jeremy P Feldman; Jeffrey S Sager; David B Badesch; John J Ryan; Daniel C Grinnan; Dianne Zwicke; Evelyn M Horn; Jean M Elwing; John E Moss; Michael Eggert; Oksana A Shlobin; Robert P Frantz; Sonja D Bartolome; Stephen C Mathai; Sula Mazimba; Steven C Pugliese; Nadine Al-Naamani
Journal:  Pulm Circ       Date:  2021-10-14       Impact factor: 2.886

4.  Elective lower limb orthopedic arthroplasty surgery in patients with pulmonary hypertension.

Authors:  Mikaela Wardle; Amanda Nair; Sarah Saunders; Iain Armstrong; Athanasios Charalampopoulos; Charlie Elliot; Abdul Hameed; Neil Hamilton; John Harrington; Carol Keen; Robert Lewis; Ian Sabroe; A A Roger Thompson; Robert M Kerry; Robin Condliffe; David G Kiely
Journal:  Pulm Circ       Date:  2022-03-25       Impact factor: 2.886

5.  EmPHasis-10 Health-Related Quality of Life and Exercise Capacity in Chronic Thromboembolic Pulmonary Hypertension After Balloon Angioplasty.

Authors:  Hayato Sakamoto; Ayumi Goda; Kazuki Tobita; Kaori Takeuchi; Hanako Kikuchi; Takumi Inami; Yuichi Tamura; Takashi Kohno; Shin Yamada; Kyoko Soejima; Toru Satoh
Journal:  J Am Heart Assoc       Date:  2022-09-03       Impact factor: 6.106

6.  Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing.

Authors:  Shelsey W Johnson; Lauren Finlay; Stephen C Mathai; Ronald H Goldstein; Bradley A Maron
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

7.  Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension.

Authors:  Allan Lawrie; Neil Hamilton; Steven Wood; Fernando Exposto; Ruvimbo Muzwidzwa; Louise Raiteri; Amélie Beaudet; Audrey Muller; Rafael Sauter; Nadia Pillai; David G Kiely
Journal:  Pulm Circ       Date:  2022-09-30       Impact factor: 2.886

8.  Symptom phenotypes in pulmonary arterial hypertension: The PAH "symptome".

Authors:  Lea Ann Matura; Jamison D Fargo; Kathleen Boyle; Jason S Fritz; Kerri A Smith; Jeremy A Mazurek; Diane Pinder; Christine L Archer-Chicko; Harold I Palevsky; Allan I Pack; Marilyn S Sommers; Steven M Kawut
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.